Overview

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-10-10
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of T-DM1 combined with CDK4/6 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Zheng Yabing
Treatments:
ribociclib